Danske Bank A S lifted its holdings in Kenvue Inc. (NYSE:KVUE – Free Report) by 34.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,610,467 shares of the company’s stock after purchasing an additional 411,200 shares during the period. Danske Bank A S owned about 0.08% of Kenvue worth $28,441,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the business. Allworth Financial LP raised its stake in Kenvue by 3.0% in the third quarter. Allworth Financial LP now owns 39,459 shares of the company’s stock worth $754,000 after buying an additional 1,152 shares in the last quarter. Eurizon Capital SGR S.p.A. lifted its holdings in Kenvue by 272.7% during the third quarter. Eurizon Capital SGR S.p.A. now owns 867,187 shares of the company’s stock worth $15,316,000 after buying an additional 634,493 shares during the period. Maryland State Retirement & Pension System lifted its holdings in Kenvue by 16.3% during the third quarter. Maryland State Retirement & Pension System now owns 115,925 shares of the company’s stock worth $2,047,000 after buying an additional 16,259 shares during the period. First Command Advisory Services Inc. boosted its position in Kenvue by 238.6% during the 3rd quarter. First Command Advisory Services Inc. now owns 8,767 shares of the company’s stock valued at $157,000 after acquiring an additional 6,178 shares in the last quarter. Finally, New York Life Investment Management LLC boosted its position in Kenvue by 2.4% during the 3rd quarter. New York Life Investment Management LLC now owns 702,125 shares of the company’s stock valued at $12,400,000 after acquiring an additional 16,254 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Kenvue Price Performance
NYSE KVUE opened at $19.31 on Tuesday. The firm’s fifty day simple moving average is $18.46 and its two-hundred day simple moving average is $18.29. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.06 and a 12-month high of $20.13. The firm has a market capitalization of $37.09 billion, a P/E ratio of 21.94, a P/E/G ratio of 1.77 and a beta of 0.48.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend was Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is currently 95.45%.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on KVUE shares. HSBC cut their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays boosted their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Finally, UBS Group increased their price target on shares of Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Ten equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.29.
Check Out Our Latest Report on Kenvue
Kenvue Profile
Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.
See Also
- Five stocks we like better than Kenvue
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
